SCHEMBL3029692

SCHEMBL3029692

Clc1ccc([C@H]2CN(Cc3ccccc3)C[C@H]2CNCc2ccc(Cl)cn2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.46
CCR5 P51681 2/20 0.42
MC4R P32245 2/20 0.41
MCHR1 Q99705 1/20 0.40
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HTR2C P28335 1/20 0.39
BCHE P06276 2/20 0.38
ACHE P22303 2/20 0.38
BACE1 P56817 2/20 0.38
ALDH1A1 P00352 1/20 0.38
DPP4 P27487 1/20 0.38
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
CXCR4 P61073 1/20 0.37
MAOA P21397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3024072 0.91 CCR5 (0.41) RORCCCR5MC4RMCHR1HDAC8
SCHEMBL3029768 0.83 RORC (0.48) RORCCCR5MC4RMCHR1ALDH1A1
SCHEMBL7889957 0.78 RORC (0.55) RORCCCR5MC4RMCHR1HTR2C
SCHEMBL3035470 0.78 RORC (0.55) RORCCCR5MC4RMCHR1HTR2C
SCHEMBL3035472 0.78 RORC (0.55) RORCCCR5MC4RMCHR1HTR2C
SCHEMBL3029693 0.77 RORC (0.46) RORCCCR5MC4RALDH1A1DPP4
SCHEMBL3647134 0.75 RORC (0.47) RORCCCR5BCHEACHEALDH1A1
SCHEMBL3029690 0.74 RORC (0.46) RORCCCR5MC4RALDH1A1DPP4
SCHEMBL3025622 0.74 ALDH1A1 (0.43) RORCCCR5ALDH1A1DPP4DRD2
SCHEMBL14921522 0.74 RORC (0.59) RORCCCR5DPP4DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2398768-B1 PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2016-08-24 EP disclosed
US-8318759-B2 Pyrrolidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-11-27 US disclosed
US-20100210659-A1 PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210659-A1 PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS OPRL1, OPRK1, OPRD1 RORC 1018/4885CCR5 1616/4885MC4R 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.